Friday, May 27, 2016 9:17:07 AM
NNVC does have employees. The work may be segregated in the cGMP facility and there may be a joint agreement for Trade Secret ownership between Theracour and NNVC, but the Trade Secrets for developing, the verification/validation (call it QC for quality control) processes for drug production scale up do exist, by virtue of the fact that the QC process for 200g production is locked down, while the QC process for 500g and larger batch sizes are in development and are of significant, proprietary value to both companies. Certainly the Trade Secrets that have been developed at the cGMP, strengthens the licensing agreements and does not circumvent those agreements. But if the company were ever to sell out to a big pharma for larger scale production, the QC Trade Secrets are the key, since they are the only proven methods to scaling up production beyond Diwan's numerous patents.
I have direct experience with Trade Secrets and I have patents myself as an employee (System Engineer) for a large company. I have gone through much training on the subjects and am versed in the laws protecting such IP. My argument is valid whether you acknowledge it or not. Some simple research on Trade Secrets makes my point:
Who Owns a Trade Secret?
A trade secret is a type of of intellectual property, and it comes in many different forms. There are no actual laws governing trade secret ownership, but trade secrets generally pertain to information held by a company rather than by an individual. So typically employers or hiring parties own trade secret information even if it is generated by an employee.
http://www.legalmatch.com/law-library/article/ownership-of-a-trade-secret.html
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM